CAR T cell therapy can now target solid tumors: Mouse study

Chimeric antigen receptor (CAR) T cell therapy, which edits a cancer patient’s T cells to recognize their tumors, has successfully helped patients with blood cancers but has yet to show the ability to treat solid tumors. To overcome this hurdle, researchers genetically engineered human T cells to produce a CAR protein that recognizes a glycopeptide found on cancer cells but not normal cells, and then demonstrated its effectiveness in mice with leukemia and pancreatic cancer.